Objective： To observe the clinical efficacy and benefit response of extracorporeal high frequency thermotherapy （EHFT） combined with Chinese medicine （CM） in the treatment of patients with advanced non-small cell...Objective： To observe the clinical efficacy and benefit response of extracorporeal high frequency thermotherapy （EHFT） combined with Chinese medicine （CM） in the treatment of patients with advanced non-small cell lung cancer. Methods： The study adopted a prospective, small sample and randomized controlled method, and the advanced non-small cell lung cancer patients were assigned to two groups according to the table of random digits, one having the treatment of EHFT combined with CM （the treatment group）, the other only with CM （the control group）. The patients in the treatment group were treated with EHFT one hour once per day, together with CM differentiation decoction, 250 mL orally taken, twice daily for 14 days as one cycle, and 3-4 cycles was performed. The patients in the control group were treated only with CM differentiation decoction using the same dose as the treatment group. The efficacies were evaluated after three to four cycles of treatment. Primary endpoints were disease control rate （DCR） and time to progression （TTP）. Secondary endpoints were overall survival time and 1-year survival rate. Results： Sixty-six patients accomplished the study. After the patients underwent different treatments, none of the patients got a complete response or partial response in both groups. In the treatment group, DCR was 72.2%, and 10 had progression of disease （28.8%）, while the DCR of the control group was 63.3%, and 11 had progression of disease （36.7%）; there was a significant statistical difference （P0.05）, suggesting that the combined regimen had superiority on the DCR. As for long-term efficacy, the median survival time （MST） of the treatment group was 7.5 months, TTP was 5.5 months, and 1-year survival rate was 21.4 %; in the control group, the results were 6.8 months, 4.5 months and 16.6% respectively. There was significant statistical difference on TTP （P0.05）, but no difference on MST or 1-year survival rate. Conclusion： EHFT combined with CM differentiation has better tolerance and short-term efficacy in the treatment of patients with advanced NSCLC.展开更多
目的:探讨射频消融(Radiofrequency ablation,RFA)联合高频热疗(External high frequency thermotherapy,HFT)和经导管动脉栓塞化疗(Transcatheter arterial chemoembolization,TACE)治疗兔肝VX2肿瘤的疗效。方法:采用移植方法建立兔肝...目的:探讨射频消融(Radiofrequency ablation,RFA)联合高频热疗(External high frequency thermotherapy,HFT)和经导管动脉栓塞化疗(Transcatheter arterial chemoembolization,TACE)治疗兔肝VX2肿瘤的疗效。方法:采用移植方法建立兔肝VX2肿瘤模型,TACE,RFA,HFT联合治疗,根据治疗方法的不同分为A组:TACE+RFA+HFT,B组:RFA+HFT组,C组:TACE+RFA,D组:TACE+HFT。结果:(1)谷丙转氨酶(ALT),谷草转氨酶(AST)在治疗组第1d均明显升高,其中A组升高幅度最大,14d内恢复最慢。B组上升幅度最小,恢复最快(P<0.05)。(2)A、B、C组治疗后肿瘤体积与治疗前比较均显著性缩小(P<0.05),而D组术后肿瘤体积显著性增大(P<0.05)。(3)病理检查结果显示A组能更好地杀死肿瘤细胞和使肿瘤组织局限化。(4)A组PI值最低、AI值和HSP70阳性表达率最高。结论:RFA+TACE+HFT能更有效地杀灭肿瘤细胞和使肿瘤组织局限化,更好地激活HSP70表达,增加机体抗肿瘤免疫的能力,改善预后。但治疗过程中肝功能波动最明显,联合运用时需综合考虑。展开更多
基金Supported by Canadian Terry Fox Run Foundation for Cancer Research
文摘Objective： To observe the clinical efficacy and benefit response of extracorporeal high frequency thermotherapy （EHFT） combined with Chinese medicine （CM） in the treatment of patients with advanced non-small cell lung cancer. Methods： The study adopted a prospective, small sample and randomized controlled method, and the advanced non-small cell lung cancer patients were assigned to two groups according to the table of random digits, one having the treatment of EHFT combined with CM （the treatment group）, the other only with CM （the control group）. The patients in the treatment group were treated with EHFT one hour once per day, together with CM differentiation decoction, 250 mL orally taken, twice daily for 14 days as one cycle, and 3-4 cycles was performed. The patients in the control group were treated only with CM differentiation decoction using the same dose as the treatment group. The efficacies were evaluated after three to four cycles of treatment. Primary endpoints were disease control rate （DCR） and time to progression （TTP）. Secondary endpoints were overall survival time and 1-year survival rate. Results： Sixty-six patients accomplished the study. After the patients underwent different treatments, none of the patients got a complete response or partial response in both groups. In the treatment group, DCR was 72.2%, and 10 had progression of disease （28.8%）, while the DCR of the control group was 63.3%, and 11 had progression of disease （36.7%）; there was a significant statistical difference （P0.05）, suggesting that the combined regimen had superiority on the DCR. As for long-term efficacy, the median survival time （MST） of the treatment group was 7.5 months, TTP was 5.5 months, and 1-year survival rate was 21.4 %; in the control group, the results were 6.8 months, 4.5 months and 16.6% respectively. There was significant statistical difference on TTP （P0.05）, but no difference on MST or 1-year survival rate. Conclusion： EHFT combined with CM differentiation has better tolerance and short-term efficacy in the treatment of patients with advanced NSCLC.
文摘目的:探讨射频消融(Radiofrequency ablation,RFA)联合高频热疗(External high frequency thermotherapy,HFT)和经导管动脉栓塞化疗(Transcatheter arterial chemoembolization,TACE)治疗兔肝VX2肿瘤的疗效。方法:采用移植方法建立兔肝VX2肿瘤模型,TACE,RFA,HFT联合治疗,根据治疗方法的不同分为A组:TACE+RFA+HFT,B组:RFA+HFT组,C组:TACE+RFA,D组:TACE+HFT。结果:(1)谷丙转氨酶(ALT),谷草转氨酶(AST)在治疗组第1d均明显升高,其中A组升高幅度最大,14d内恢复最慢。B组上升幅度最小,恢复最快(P<0.05)。(2)A、B、C组治疗后肿瘤体积与治疗前比较均显著性缩小(P<0.05),而D组术后肿瘤体积显著性增大(P<0.05)。(3)病理检查结果显示A组能更好地杀死肿瘤细胞和使肿瘤组织局限化。(4)A组PI值最低、AI值和HSP70阳性表达率最高。结论:RFA+TACE+HFT能更有效地杀灭肿瘤细胞和使肿瘤组织局限化,更好地激活HSP70表达,增加机体抗肿瘤免疫的能力,改善预后。但治疗过程中肝功能波动最明显,联合运用时需综合考虑。
